247 results about "Epithelial tissue" patented technology

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

Systems and methods analyzing body fluids contain cells including blood, bone marrow, urine, vaginal tissue, epithelial tissue, tumors, semen, and spittle are disclosed. The systems and methods utilize an improved technique for applying a monolayer of cells to a slide and generating a substantially uniform distribution of cells on the slide. Additionally aspects of the invention also relate to systems and method for utilizing multi-color microscopy for improving the quality of images captured by a light receiving device.

The present invention relates to a method of treated disordered epithelial tissues such as cold sores and other complications resulting from disorders such as herpes, and the like. The inventive method combines an anti-infective and/or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and/or antimicrobial active agent is an organohalide such as a quaternary ammonium compound, preferably benzalkonium chloride. The inventive method may be used also in connection with a preferred applicator configuration.

Methods for preventing damage to epithelial tissue during PDT induced using a photosensitizing agent or pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control photoactivation of the photoactive species to protect the epithelial tissue. In one embodiment, epithelial tissue surrounding a targeted treatment site can be protecting by decreasing the oxygen-content in the tissue, thereby preventing the conversion of the photosensitizer into the phototoxic species in the epithelial tissue.

The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

The present invention relates to biocompatible microemulsion systems designed for controlled release drug delivery applications formulated with phospholipids such as lecithin (surfactant), a lipophilic additive (linker) containing 9 or more carbons in their alkyl group and hydrophilic-lipophilic balance (HLB) of 5 or less, and a surfactant-like hydrophilic additive (linker) containing between 6 to 9 carbon atoms in their alkyl tail. The combination of linkers and phospholipids produce formulations capable of delivering high concentrations of poorly soluble drugs into epithelial tissue using low surfactant concentrations, with minimum cytotoxic side effects.

The invention provides a system, devices, and methods for ablating abnormal epithelial tissue of the uterine cervix. Embodiments of an ablation device include an operative head with a support surface adapted to conformably engage and therapeutically contact the cervix, and an energy delivery element on the support surface. The energy delivery element is configured to deliver energy, such as RF energy, to the tissue in a manner that controls the surface area and depth of ablation. The device may further include a shaft and a handle to support the ablation device, and may further include a speculum to facilitate access to the cervix. A system to support the operation of the ablation device includes a generator to deliver energy to the energy delivery element. Embodiments of a method for ablating abnormal cervical tissue include inserting an ablation device intravaginally to contact the cervix, aligning an energy delivery element support surface conformably against a region of the cervix with abnormal tissue, and ablating the tissue.

In an embodiment of the invention, a frictional tissue sampling device with an expandable balloon and associated abrasive material can be used to obtain tissue biopsy samples. A frictional tissue sampling device with expandable abrasive material can be used to obtain an epithelial tissue biopsy sample from lesions. The device can be otherwise used to sample specific locations. In various embodiments, the head of the device can be passes through a catheter into a body canal to sample epithelial tissue.

A pharmaceutical composition, method and apparatus for treatment, diagnosis or both treatment and treatment of hyperproliferative malignant and non-malignant diseases of epithelial tissues is disclosed. The invention comprises local application of the pharmaceutical composition to a predetermined area of the tissue characterized by complete and consistent coverage of the tissue, including irregularly shaped tissue. The pharmaceutical composition consists of an active component, such as a photosensitizer or a precursor thereof, and at least one carrier substance including a viscous fluid, a gel, or a fluid that becomes viscous upon contact with the tissue. The gel's viscosity allows it to adhere to the tissue for a sufficient amount of time to transfer the photosensitizer or precursor. In a preferred embodiment the pharmaceutical composition is sprayed onto the surface of the diseased tissue. Optionally, a mechanical device is used to further restrict the composition to a specific areas and can also be used to press the composition onto the tissue. In another embodiment, components of the composition are delivered to and mixed at the treatment site by a suitable delivery device prior to irradiation. The active component is then activated by a suitable wavelength of radiation.

A system and method are provided for preventing damage to the epidermis or other epithelial or non-target tissue during photodynamic therapy treatment. For example, an inhibiting radiation can be used to control formation of a photosensitizer from a precursor photosensitizer in the epidermis or epithelial tissue. Subsequent application of a treatment radiation can activate the photosensitizer to damage or destroy target sites while the non-target tissue remains substantially unaffected.

An apparatus (10) adapted to contact epithelial tissue, the apparatus comprising a cup (12) having a concave shape and adapted to be positioned on epithelial tissue, the cup capable of maintaining a reduced air pressure and holding a volume of flowable material; and an electrical support structure (14) comprising a support structure and a plurality of sensors, electrodes, or both (15) configured to interact with epithelial and subepithelial tissue.

In an embodiment of the invention, a frictional tissue sampling device with a head designed to be rotated without rotating off the designated site can be used to obtain tissue biopsy samples. A frictional tissue sampling device with a head designed to be rotated without rotating off the designated site can be used to obtain an epithelial tissue biopsy sample from lesions. The device can be otherwise used to sample specific locations. In various embodiments, the head of the device is narrow and pointed with a hybrid pear shaped diamond facet. Abrasive material can be adhered to the facet.

The invention relates to polypeptides and nucleic acids encoding these and to their use for the diagnosis, prevention and/or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.

The present invention involves methods and compositions for increasing the susceptibility of target cells to transduction by gene transfer vectors. Specifically, it is proposed that increasing intracellular permeability in epithelial tissue increases the percentage of input vector that will transduce that target tissue. Specific examples show that receptors for retrovirus are preferentially accessible on the basolateral surface of airway epithelia, and permeabilizing such tissues results in greater infection with retrovirus. This has important implications in gene therapy, for example, to treat cystic fibrosis with the CFTR gene.

Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.

An image of an individual (2) is obtained using a digital camera (1). The image data is then processed by ratio determination module (10) and an image conversion module (12) to analyze the image and determine data representative of the distribution of blood and melanin in the skin of the imaged individual. This chromophore distribution data is then processed by an image generation module (18) which generates an image representative of the expected appearance of epithelial tissue having the determined distribution of chromophores where the epithelial tissue is under fixed illumination and has a flat spatial geometry and where all the identified melanin is present solely in the epidermis. The presence of dermal melanin can then be identified by comparing the original image data and the image derived from processing the calculated chromophore distributions and identifying where the ratio of these images differs by more than a threshold, the threshold being set at a level above the amount of variation expected due to lighting and geometry differences.

The invention relates to a cell chemical dyeing method compatible with immunofluorescence analysis and relative applications. The invention further relates to a method for checking epithelial tissue source tumor cell in human peripheral blood sample, which uses the cell chemical dyeing method compatiable with immunofluorescence analysis. The inventive check method can simply, quickly and accurately check the tumor cells of epithelial tissue source in blood circulation from the karyocyte separated from small human periphery blood sample.

A method for determining the relative benefits of products which affect animal epithelial tissue is provided. Also provided is a method for evaluating quantitative changes on one or more affected surfaces of epithelial tissue of a subject caused by a test product.

The invention relates to trans-epithelial frictionally abrasive tissue sampling devices for performing biopsies and methods of inducing an immune response against a pathogen, wherein epithelial cells containing the pathogen are disrupted with the frictionally abrasive tissue sampling device to introduce the pathogen into the bloodstream of a patient.

Targeting molecules are provided for use in delivering imaging agents to epithelial tissue. The targeting molecule comprises a polypeptide that forms a closed covalent loop, contains at least three peptide domains having β-sheet character, each of the domains being separated by domains lacking β-sheet character. The targeting molecule specifically binds to a basolateral factor attached to a basolateral domain of an epithelial cell surface causing internalization of a linked imaging agent into the cells. The polypeptide or imaging agent may be linked to a peptide amino acid sequence that directs delivery of the imaging agent to a carcinoma cell, a nucleus, or an endoplasmic reticulum.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

The invention discloses a method for screening new internal reference molecules suitable for cervical tissue micro RNA real-time fluorescence quantitative PCR research. The method comprises the following technical steps: screening human Micro RNA probes by using a Micro RNA chip, and selecting Micro RNAs with constant normal tissue expression and high expression abundance of cervical cancer and cervix as candidate internal references; selecting a normal cervical epithelial tissue and a cancerous cervical tissue as clinical cervical tissue specimens respectively, and verifying the specimens by using fluorescence quantitative PCR; and analyzing data by using two special internal reference analysis software comprising geNorm software and Norm Finder so as to discover the internal reference molecules suitable for cervical tissue Micro RNA research. The internal reference molecules screened and verified by using the method of the invention can avoid possible differences of different cervical tissue specimens on the yield, quality and reverse transcription efficiency of the RNA, well correct and standardize the data for real-time fluorescence quantitative PCR detection, and improve the accuracy and the reliability of the search.